HSCS Stock Analysis: Buy, Sell, or Hold?
HSCS - HeartSciences Inc. Common Stock
$2.79
-0.15 (-5.10%)
▼
5d:
-6.69%
30d:
+34.78%
90d:
+18.22%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 23, 2026
19d
Get Alerted When HSCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: HSCS is 8.1% above its trading range ($2.58). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: HSCS is 8.1% above its trading range ($2.58). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: HSCS is currently trading at $2.79, which is considered extended relative to its 30-day fair value range of $1.72 to $2.58.
Technical Outlook: Technically, HSCS is in a strong downtrend. The price is approaching resistance at $2.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: HSCS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+258.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HSCS is in a strong downtrend. The price is approaching resistance at $2.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: HSCS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+258.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.72 -
$2.58
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BEARISH: Price extended above range (+8.1% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 258.4% below Wall St target ($10.00)
- CAUTION: 5-day price weakness (-6.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.72 -
$2.58
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.63
Resistance Level
$2.24
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.99
Wall Street Target
$10.00
(+258.4%)
Revenue Growth (YoY)
653.8%
Share & Embed Analysis
Last updated: July 02, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HSCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
